HEXAXIM
Suspension for Injection 1 x 0 5 mL
registration number
46/30.1/0447
What HEXAXIM is and what it is used for
HEXAXIM (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b (such as meningitis, septicaemia, cellulitis, arthritis, epiglottitis, respiratory illness (pneumopathy), osteomyelitis).
HEXAXIM does not protect against infectious diseases caused by other types of Haemophilus influenzae or against meningitis of other origins.
dosage
Primary vaccination:
The South African Official Guidelines recommend a three-dose primary vaccination schedule.
The primary vaccination schedule consists of three doses of 0,5 mL (such as 6, 10, 14 weeks; 2, 3, 4 months; 3, 4, 5 months; 2, 4, 6 months) with an interval of at least 4 weeks or two doses of 0,5 mL (such as 3, 5 months) with an interval of at least 8 weeks.
All vaccination schedules including the WHO Expanded Programme on Immunisation (EPI) (at 6, 10, 14 weeks of age) can be used whether or not a dose of hepatitis B vaccine has been given at birth.
Where a dose of hepatitis B vaccine is given at birth, HEXAXIM can be used for supplementary doses of hepatitis B vaccine from the age of six weeks. If a second dose of hepatitis B vaccine is required before this age, monovalent hepatitis B vaccine should be used.
When a dose of hepatitis B vaccine is given at birth, the sequential infant primary vaccination hexavalent/pentavalent/hexavalent schedule with HEXAXIM and a pentavalent DTaP-IPV/Hib vaccine can be used in accordance with official recommendations.
Booster vaccination:
A booster dose should be given at least 6 months after the priming dose and in accordance with the official recommendation. At the very least, a dose of Hib must be administered.
After a 3-dose primary vaccination schedule of HEXAXIM (such as 6, 10, 14 weeks; 2, 3, 4 months; 3, 4, 5 months; 2, 4, 6 months), a booster dose should be given, preferably during the second year of life, at least 6 months after the last priming dose.
After a 2-dose primary vaccination schedule with HEXAXIM at 3 and 5 months, a booster dose must be given.
When hepatitis B vaccine is given at birth, after a 3-dose primary series (i.e. 6, 10, 14 weeks; 2, 3, 4 months; 3, 4, 5 months; 2, 4, 6 months), HEXAXIM or a pentavalent DTaP-IPV/Hib vaccine can be administered for the booster.
In the absence of hepatitis B vaccination at birth and after a 3-dose EPI schedule (6, 10, 14 weeks), hepatitis B vaccine booster must be given. HEXAXIM can be considered for the booster.
In the absence of hepatitis B vaccination at birth and after a 2-dose or 3-dose schedule at 3 and 5 or 2, 3, 4; or 3, 4, 5; or 2, 4, 6 months, it is preferable to give a hepatitis B vaccine booster dose. HEXAXIM can be considered for the booster.
Paediatric population:
This vaccine may be considered until the age of 5 years.
how to take
HEXAXIM should be administered intramuscularly. The recommended injection sites are the antero-lateral aspect of the upper thigh (preferred site) in infants and toddlers or the deltoid muscle in older children (possibly from 15 months of age).
In infants presenting with low body mass and/or low muscle mass (born pre-term or with low body mass conditions) the use of adapted needles (more than 23G and with a reduced length of 16 mm) should be considered to avoid bone injuries while maintaining intra-muscular delivery (see section 4.4).
Do not administer via intravascular route. Ensure that the needle does not penetrate a blood vessel (see section 4.4).
Separate syringes, separate injection sites and preferably separate limbs must be used in case of concomitant administration with other vaccines (see section 4.5).
For instructions on handling, see section 6.6.
What HEXAXIM contains
Each 0,5 mL adjuvanted dose contains*:
Purified diphtheria toxoid ≥ 20 IU1 (30 Lf)
Purified tetanus toxoid ≥ 40 IU2,3 (10 Lf)
Bordetella pertussis antigens
- Pertussis toxoid 25 μg
- Filamentous haemagglutinin 25 μg
Inactivated poliomyelitis virus:
- Type 1 (Mahoney) D antigen: 40 units
- Type 2 (MEF 1) D antigen: 8units
- Type 3 (Saukett) D antigen: 32 units
Hepatitis B surface antigen 10 μg
Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate), conjugated to tetanus protein [tetanus protein: 22 – 36 μg]: 12 μg (expressed as amount of polysaccharide)
Refer to Section 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Contains Sugar (11 mg sucrose per 0,5 mL dose)
The vaccine may contain traces of glutaraldehyde, formaldehyde, neomycin, streptomycin and polymyxin B which are used during the manufacturing process (see section 4.3).
other ingredients
Disodium hydrogen phosphate
Potassium dihydrogen phosphate
Essential amino acids including L-phenylalanine
Trometamol
Sucrose
Sodium hydroxide (for pH adjustment)
Acetic acid (for pH adjustment)
Hydrochloric acid (for pH adjustment)
Water for injection.
Therapeutic classification
J07CA09.